Table 2.
Patient characteristics after propensity score matching
| Characteristic | All patients | ATEZO/BEVA | LEN | p value |
|---|---|---|---|---|
| N | 304 | 152 | 152 | |
| Age, years | 74 (31–93) | 73 (51–93) | 75 (31–93) | 0.351 |
| Sex (female/male) | 59/245 | 34/118 | 25/127 | 0.198 |
| BMI, kg/m2 | 23.3 (13.6–38.9) | 23.3 (17.0–33.8) | 23.4 (13.6–38.9) | 0.399 |
| Etiology (HBV/HCV/non B, C) | 47/121/136 | 22/61/69 | 25/60/67 | 0.891 |
| ALBI score | −2.44 (−3.77 to −1.45) | −2.43 (−3.77 to −1.55) | −2.48 (−3.54 to −1.59) | 0.835 |
| ALBI grade (1/2a/2b) | 115/83/107 | 58/41/53 | 57/41/54 | 0.991 |
| Tumor diameter, mm (< 30/≥ 30) | 145/159 | 71/81 | 74/78 | 0.730 |
| Number of tumors (< 5/≥ 5) | 121/183 | 64/88 | 57/95 | 0.412 |
| BCLC stage (A/B/C) | 10/159/135 | 4/81/67 | 6/78/68 | 0.791 |
| Macrovascular invasion (no/yes) | 240/64 | 121/31 | 119/33 | 0.778 |
| Extrahepatic spread (no/yes) | 212/92 | 109/43 | 103/49 | 0.453 |
| AFP, ng/mL | 32.0 (0.9–272,264) | 25.7 (1.0–272,264) | 35.7 (0.9–252,348) | 0.924 |
| Number of registered patients (high VC/middle VC/low VC) | 132/54/60 | 67/25/65 | 65/29/58 | 0.834 |
Data are expressed as median (range), or number
ATEZO/BEVA atezolizumab plus bevacizumab, LEN lenvatinib, BMI body mass index, HBV hepatitis B virus, HCV hepatitis C virus, ALBI albumin-bilirubin, BCLC Barcelona Clinic Liver Cancer, AFP α-fetoprotein, VC volume center